OpGen IncNASDAQ:OPGNNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6161
- TODAY'S CHANGE (%)0.0162 (2.7005%)
- Bid / Lots0.5810/ 20
- Ask / Lots0.6161/ 28
- Open / Previous Close0.5850 / 0.5999
- Day Range
- 52 Week Range
- Volume205,523
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OPGN |
|---|---|---|
| 09:32 ET | 22117 | 0.58 |
| 09:34 ET | 3500 | 0.57 |
| 09:36 ET | 3187 | 0.565 |
| 09:38 ET | 3700 | 0.57 |
| 09:39 ET | 19284 | 0.57 |
| 09:41 ET | 1402 | 0.57 |
| 09:45 ET | 615 | 0.570259 |
| 09:52 ET | 14000 | 0.5706 |
| 09:54 ET | 1029 | 0.57 |
| 09:57 ET | 2300 | 0.6099 |
| 09:59 ET | 1945 | 0.571 |
| 10:01 ET | 100 | 0.6099 |
| 10:03 ET | 100 | 0.6099 |
| 10:06 ET | 2141 | 0.609899 |
| 10:08 ET | 993 | 0.6 |
| 10:10 ET | 346 | 0.6081 |
| 10:12 ET | 100 | 0.6099 |
| 10:14 ET | 400 | 0.6099 |
| 10:17 ET | 347 | 0.6099 |
| 10:24 ET | 347 | 0.570301 |
| 10:32 ET | 380 | 0.5705 |
| 10:33 ET | 4682 | 0.6 |
| 10:39 ET | 938 | 0.59 |
| 10:44 ET | 433 | 0.6 |
| 11:20 ET | 140 | 0.591 |
| 11:22 ET | 100 | 0.5901 |
| 11:31 ET | 925 | 0.59 |
| 11:42 ET | 200 | 0.571 |
| 11:51 ET | 2000 | 0.58 |
| 12:00 ET | 1805 | 0.58 |
| 12:02 ET | 1718 | 0.5791 |
| 12:07 ET | 100 | 0.59 |
| 12:09 ET | 100 | 0.59 |
| 12:14 ET | 14678 | 0.590201 |
| 12:16 ET | 100 | 0.6 |
| 12:18 ET | 100 | 0.6 |
| 12:20 ET | 1500 | 0.59505 |
| 12:21 ET | 100 | 0.6 |
| 12:23 ET | 100 | 0.6 |
| 12:36 ET | 168 | 0.600199 |
| 12:57 ET | 200 | 0.582 |
| 01:33 ET | 1000 | 0.582 |
| 02:58 ET | 368 | 0.5803 |
| 03:16 ET | 100 | 0.6098 |
| 03:32 ET | 550 | 0.609 |
| 03:34 ET | 752 | 0.6099 |
| 03:41 ET | 100 | 0.5901 |
| 03:52 ET | 200 | 0.5999 |
| 03:54 ET | 1030 | 0.599 |
| 03:56 ET | 3955 | 0.61 |
| 03:57 ET | 800 | 0.61 |
| 03:59 ET | 6656 | 0.6161 |
Mar 25, 2024
DJ OpGen Investor David Lazar Is Named CEO, from 4:30PM ET on Monday Mar 25, 2024 by Dow Jones
4:30PM ET on Monday Mar 25, 2024 by Dow JonesOpGen Announces Acquisition of Preferred Stock by David Lazar, from 4:05PM ET on Monday Mar 25, 2024 by Dow Jones
4:05PM ET on Monday Mar 25, 2024 by Dow Jones*DJ OpGen Announces Acquisition Of Preferred Stock By David Lazar >OPGN, from 4:05PM ET on Monday Mar 25, 2024 by Dow Jones
4:05PM ET on Monday Mar 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
OpGen Inc | 6.0M | -0.1x | --- |
Xenetic Biosciences Inc | 5.9M | -1.5x | --- |
AquaBounty Technologies Inc | 6.7M | -0.2x | --- |
Seelos Therapeutics Inc | 4.5M | 0.0x | --- |
Trevena Inc | 7.4M | -0.1x | --- |
Helix BioMedix Inc | 5.2M | -1.5x | --- |
Company Information
OpGen, Inc. (OpGen) is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Company’s product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE- in vitro diagnostics (IVD)-marked polymerase chain reaction (PCR)-based severe acute respiratory syndrome (SARS)-CoV-2 test kit. The Company’s subsidiaries include Curetis GmbH and Ares Genetics GmbH.
Contact Information
- Headquarters
- 9717 Key West Avenue, Suite 100ROCKVILLE, MD, United States 20850
- Phone
- 301-869-9683
- Fax
- 301-869-9684
Executives
- Chairman of the Board, Chief Executive Officer
- David Lazar
- Chief Financial Officer, Corporate Secretary
- Albert Weber
- Chief Operating Officer
- Johannes Bacher
- Independent Director
- Avraham Ben-tzvi
- Independent Director
- Matthew Mcmurdo
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.0M |
|---|---|
Revenue (TTM) | $3.1M |
Shares Outstanding | 10.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.64 |
EPS | $-6.51 |
Book Value | $52.25 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 2.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -772.84% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
